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Abstract
Background: Previous randomized controlled trials demonstrated a protective effect of renin angiotensin system
blocking agents for the development of type-2 diabetes in patients with pre-diabetes. However, there are no real-
world data available to illustrate the relevance for clinical practice.
Methods: Open, prospective, parallel group study comparing patients with an ACE inhibitor versus a diuretic based
treatment. The principal aim was to document the first manifestation of type-2 diabetes in either group.
Results: A total of 2,011 patients were enrolled (mean age 69.1 ± 10.3 years; 51.6% female). 1,507 patients were
available for the per-protocol analysis (1,029 ramipril, 478 diuretic group). New-onset diabetes was less frequent in
the ramipril than in the diuretic group over 4 years. Differences were statistically different at a median duration of
3 years (24.4% vs 29.5%; p < 0.05). Both treatments were equally effective in reducing BP (14.7 ± 18.0/8.5 ± 8.2
mmHg and 12.7 ± 18.1/7.0 ± 8.3 mmHg) at the 4 year follow-up (p < 0.001 vs. baseline; p = n.s. between groups).
In 38.6% and 39.7% of patients BP was below 130/80 mmHg (median time-to-target 3 months). There was a
significant reduction of cardiovascular morbidity and mortality in favour of ramipril (p = 0.033). No significant
differences were found for a change in HbA1c as well as for fasting blood glucose levels during follow-up. The rate
of adverse events was higher in diuretic treated patients (SAE 15.4 vs. 12.4%; p < 0.05; AE 26.6 vs. 25.6%; p = n.s).
Conclusions: Ramipril treatment is preferable over diuretic based treatment regimens for the treatment of
hypertension in pre-diabetic patients, because new-onset diabetes is delayed.
Background
About 20% of patients with hypertension will develop
type 2 diabetes in a three year period [1] and hyperten-
sion is a frequent co-morbid condition in patients with
pre-diabetes and the metabolic syndrome [2,3]. While
patients with pre-diabetes have an increased risk of cor-
onary heart disease or stroke already [4], there is a
further substantial increase in cardiovascular risk when
diabetes actually develops [5,6] and the presence of
hypertension multiplies this risk by a factor of three [7].
It was therefore important to recognize that diabetes
development may be prevented by preferring blockers of
the renin angiotensin system (RAS) as opposed to older
treatment options such as betablockers and diuretics
which promoted its development [8]. Calcium channel
blockers were neutral with this respect as shown in a
supplemental analysis by Lam [9]. This was learned
from a number of trials reporting significant reductions
in the incidence of type 2 diabetes with renin-angioten-
sin blocking treatment strategies in comparison to pla-
cebo, diuretics or betablockers [1,10-17]. Most of these
analyses were however post-hoc and endpoints not pre-
defined or the development of diabetes not the primary
endpoint. Trials with a pre-defined new-onset diabetes
endpoint were ASCOT-BPLA [14,15], VALUE [16],
DREAM [1] and, more recently, NAVIGATOR [17].
While there was a significant reduction of new onset
diabetes in ASCOT-BLPA (HR 0.70; 95%CI 0.63-0.78),
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(HR 0.86; 95%CI 0.80-0.92), there was none in DREAM
(HR 0.91 [95%CI 0.80-1.03]).
Because there is no large scale study on the effectiveness
of blocking the RAS for the prevention of diabetes in “real
world” clinical practice [18-20] we designed the ACE inhi-
bitor-based versus diuretic-based antihypertensive primary
treatment in patients with prediabetes (ADaPT) study. We
aimed to verify, that the perceived benefits of using a RAS
based regimen over diuretics for the treatment of hyper-
tension in patients with pre-diabetes are also seen in clini-
cal practice. Patients were selected based on a high risk for
the development of type 2 diabetes according to the modi-
fied PreDiSc Score [21].
Methods
Design
ADaPT is an open, prospective, non-randomised parallel
group observation at 150 office based general physicians
and internists. A detailed description of the design of the
ADaPT investigation has been published previously [22].
The study complies with § 67(6) of the German Drug
Law and was performed under the auspices of the
German Hypertension League. Ethical approval was
obtained by the institutional review board of the Charité,
Berlin, Germany. Patients had to provide written
informed consent prior to entering the study.
Patient population
Inclusion criteria for ADaPT were based on the PreDisc
Score [21]: Age ≥ 45 years (amended, original protocol
≥ 55 years), systolic blood pressure ≥ 140 and/or diasto-
lic blood pressure ≥ 90 mmHg, fasting glucose (IFG)
level 110-125 mg/dl in venous plasma or 100-109 mg/dl
in capillary whole blood and an HbA1c of 6-6.5% within
the last six months. Patients with higher blood glucose
levels than mentioned above, with overt diabetes or anti-
diabetic drug treatment were excluded as well as
patients with congestive heart failure, chronic renal
insufficiency, history of myocardial infarction, stroke,
drug or alcohol abuse or contraindications against any
of the principal drugs applied. Patients in group 1
received ramipril either as monotherapy or in combina-
tion with felodipine or another calcium channel blocker,
patients in group 2 any other diuretic with or without
beta-blocker-based therapy without using renin angio-
tensin blocking agents. Assignment of patients to either
group was at the discretion of the treating physician
(non-randomized). In case of inadequate response a
dose increase or addition of further combination drugs
was allowed within the approved labelling and in accor-
dance with the recommendations of the European
Society of Hypertension [23].
Endpoints
The primary evaluation criterion of ADaPT was the first
manifestation of type 2 diabetes (fasting glucose level ≥
126 mg/dl/≥ 7.0 mmol/l). Blood glucose related further
criteria were the deterioration of pre-diabetes indicated
by an increase of HbA1c of at least 10% over baseline,
an increase of fasting glucose levels and a change of
HbA1c. All laboratory values were analyzed in a central
core laboratory. Blood pressure related criteria were
achievement of a target BP < 130/80 mm Hg and the
time needed to reach target. Major cardiovascular events
and mortality as well as the type and frequency of
adverse or serious adverse events (AE/SAE) were also
recorded.
Statistical analyses
Data were obtained on a paper case report form and
entered into a Microsoft Access 2003 database. Analyses
were conducted with SPSS 17.0. Patients treated with
ramipril (or ramipril-based combination therapies) and
patients who received various a diuretic based treatment
strategy (with the exception of ACEi or ARBs) were com-
pared using descriptive statistics for continuous target
data per treatment group and per total including the fol-
lowing: number of patients, means ± standard deviation,
or median. The absolute and relative frequencies in per-
centages were determined. For a comparison of the treat-
ment groups with respect to the incidence of specific
events (e.g. patients with first manifestation of diabetes
mellitus type 2 or proportion of patients with deterioration
of pre-diabetes), the chi-square or the log-rank tests was
used.
Results
Between August 2004 and March 2006 a total of 2,108
patients were enrolled. Ninety-seven had to be excluded
because of violations against the study protocol resulting
in 2,011 patients available for the intention to treat analy-
sis - 1,350 patients were allocated to a ramipril based and
661 patients to a diuretic based therapy. The per-protocol
analysis (1,507 patients) excluded all ramipril patients,
who had received any diuretic or a beta-blocking agent
and all patients of the diuretic group with concomitant
ACEi or ARBs. In the ramipril group 15.3% received cal-
cium channel blocker and no patient in the diuretic group
received a betablocker. Of these 1,394 patients were avail-
able for the 1 year follow-up, 1,286 for the 2 year, 1,040
patients for the 3 year and 483 for the 4 year follow-up.
Patient characteristics
Patients enrolled (ITT, 2,011 patients) had a mean age
of 69.1 ± 10.3 years, and 51.6% were female. The mean
BMI was 29.9 ± 4.9 kg/m2, which meant that 41.7%
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female patients in the diuretic group (p < 0,001) all
other characteristics, risk factors, laboratory values and
co-medication were comparable in the two study groups
(Table 1 & 2).
Office blood pressure at baseline was 147.4 ± 15.9/
87.3 ± 9.3 mmHg in the ramipril group and 144.6 ±
15.3/86.5 ± 9.4 mmHg in the diuretic group (p < 0.001/
p = n.s.). Daytime ambulatory blood pressure was 138.2
± 15.1/81.4 ± 10.0 with ramipril and 135.0 ± 15.0/80.4 ±
10.8 with diuretics (p = 0.001/p = n.s.; Table 3).
The mean fasting glucose at baseline was 94.4 ± 21.3
mg/dl in the ramipril and 95.5 ± 21.0 mg/dl in the
diuretic group (p = n.s.). HbA1c was 5.6 ± 0.6% and 5.7
± 0.7% respectively (p = n.s.). While none of the patients
had diabetes at enrolment, 37.0% of ramipril treated and
40.4% of diuretic treated patients had a family history of
diabetes (p = n.s.).
Patient characteristics of the per-protocol (PP) popula-
tion were essentially identical to the ITT population
( T a b l e s1 ,2 ,3 ) .T h eo n l yn o t e w o r t h yd i f f e r e n c e sw e r e
the lesser use of calcium channel blockers (0 vs. 13.8%)
in the diuretic group in the PP population.
Primary endpoint
The primary evaluation criterion was the first manifes-
tation of type 2 diabetes defined as a fasting glucose
level ≥ 126 mg/dl/≥ 7.0 mmol/l. The prevalence of
type-2 diabetes was 0% at baseline (per exclusion cri-
teria). Incidence rates were consistently higher in the
diuretic than in the ramipril group through years 1 to
4. Strikingly however, incidence rates were 16.9 and
18.2% in the first year and between 2.5 and 7.6% in
subsequent years 2 to 4. The prevalence rose continu-
ously during follow-up (Figure 1) reaching statistical
significance at a median treatment duration of three
Table 1 Patient characteristics and co-morbidity at baseline
Intention to treat Per protocol
Ramipril
(n = 1,350)
Diuretic
(n = 661)
Ramipril
(n = 1,029)
Diuretic
(n = 478)
Age (years ± SD) 69.4 ± 10.4 68.5 ± 10.3 69.4 ± 10.5 67.8 ± 10.3
Female (%) 48.7 57.5 48.5 58.4
BMI (kg/m
2 ± SD) 29.9 ± 5.0 29.8 ± 4.8 29.8 ± 5.0 29.7 ± 4.9
Risk factors*
Dyslipidemia (%) 56.4 56.6 54.7 56.9
Hyperuricemia (%) 21.7 23.0 20.5 20.5
CAD (%) 13.9 14.2 11.7 13.6
COPD (%) 6.7 4.8 6.8 5.4
Microalbuminuria (%) 6.2 5.4 6.2 5.6
Kidney disease (%) 3.0 2.9 2.8 2.1
Smoking (%) 15.6 14.4 15.6 14.4
Diabetes
Diabetes (%) 0 0 0 0
Family history (%) 37.0 40.4 37.2 41.4
Laboratory values
Total cholesterol (mg/dl ± SD) 222.4 ± 43.4 222.5 ± 41.8 223.4 ± 42.0 224.1 ± 41.9
HDL-cholesterol (mg/dl ± SD) 61.7 ± 16.0 61.8 ± 15.3 62.5 ± 16.1 61.7 ± 15.6
LDL-cholesterol (mg/dl ± SD) 128.6 ± 35.6 127.2 ± 34.2 129.3 ± 35.4 128.6 ± 34.1
Triglycerides (mg/dl ± SD) 169.1 ± 168.3 172.8 ± 127.5 161.8 ± 97.8 175.2 ± 137.6
Fasting blood glucose
(mg/dl ± SD)
94.4 ± 21.3 95.5 ± 21.0 94.1 ± 21.3 95.7 ± 21.5
HbA1c (% ± SD) 5.6 ± 0.6 5.7 ± 0.7 5.6 ± 0.6 5.6 ± 0.7
Serum-creatinine (mg/dl ± SD) 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.3
Albuminuria
(mg/g creatinine ± SD)
33.1 ± 121.6 24.6 ± 56.3 33.8 ± 131.4 19.4 ± 38.2
Urinary creatinine (mg/dl ± SD) 123.6 ± 72.7 122.7 ± 74.0 123.3 ± 72.4 120.6 ± 71.6
Cystatin-C (mg/dl ± SD) 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.3
hs-CRP (mg/dl ± SD) 5.2 ± 8.7 5.3 ± 14.2 5.1 ± 8.5 5.6 ± 16.0
Legend. * available cases only (about 12% for microalbuminuria, about 1% for the other variables); SD, standard deviation; BMI, body mass index; CAD, coronary
artery disease; COPD, chronic obstructive pulmonary disease; HDL, high density lipoprotein; LDL, low density lipoprotein; CRP, C-reactive protein
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ference at 4 years was largely preserved (Δ 3.5%), but
became non-significant.
Secondary blood pressure - related endpoints
Ramipril and diuretic based antihypertensive treatments
were about equally effective in lowering blood pressure
(Figure 2) using office blood pressure measurement. At
a mean baseline blood pressure of 147.2 ± 15.7/87.4 ±
9.1 mmHg in the ramipril and 144.6 ± 15.3/86.9 ± 9.4
mmHg in the diuretic group (Table 3) blood pressure
was reduced by 14.7 ± 18.0/8.5 ± 8.2 mmHg and 12.7 ±
18.1/7.0 ± 8.3 mmHg at the 4 year follow-up (p < 0.001
vs. baseline; p = n.s. between groups).
79.8% of patients in the ramipril and 77.0% of patients
in the diuretic group achieved a target blood pressure of
< 140/90 mmHg at the 4 year follow-up. In 38.6% and
39.7% of patients respectively blood pressure was below
130/80 mmHg. The median time to reach a target BP of
130/80 mmHg was 3 months in either group (p = n.s.).
Secondary glucose - related endpoints
Laboratory assessments were performed every year. No
data were available on the initiation of antidiabetic med-
ication during follow-up.
Fasting glucose levels at baseline were about equal in
both groups (94.1 mg/dl in the ramipril group, 95.7 mg/dl
in the diuretic group; p = n.s.). Values remained rather
stable over the 4 year observational period; both within
group comparisons showed a trend towards slightly lower
values after year 4 in the ramipril group but were not
significant (Figure 3, upper panel).
HbA1c values at baseline were 5.6 ± 0.6 in the rami-
pril and 5.6 ± 0.7 in the diuretic group (p = n.s.) and
remained virtually similar between groups throughout
the 4 year observation. There was however a gradual
Table 3 Blood pressure at baseline
Intention to treat Per protocol
Ramipril Diuretic Ramipril Diuretic
Office blood pressure
RR systolic (mmHg ± SD) 147.4 ± 15.9 144.6 ± 15.3 147.2 ± 15.7 144.6 ± 15.3
RR diastolic (mmHg ± SD) 87.3 ± 9.3 86.5 ± 9.4 87.4 ± 9.1 86.9 ± 9.4
HR (bpm ± SD) 73.9 ± 9.4 73.0 ± 9.8 74.3 ± 9.2 73.5 ± 9.8
Daytime ABPM
RR systolic (mmHg ± SD) 138.2 ± 15.1 135.0 ± 15.0 138.7 ± 15.3 134.7 ± 14.5
RR diastolic (mmHg ± SD) 81.4 ± 10.0 80.4 ± 10.8 81.4 ± 10.0 80.3 ± 10.4
HR (bpm ± SD) 76.3 ± 10.5 73.6 ± 11.3 76.4 ± 10.4 73.5 ± 11.5
Nighttime ABPM
RR systolic (mmHg ± SD) 126.7 ± 17.2 122.4 ± 17.9 126.6 ± 17.3 122.4 ± 17.9
RR diastolic (mmHg ± SD) 72.4 ± 11.2 70.2 ± 11.1 72.1 ± 11.2 70.0 ± 10.7
HR (bpm ± SD) 67.3 ± 9.8 66.1 ± 9.9 67.2 ± 9.5 65.9 ± 9.9
Legend. RR, Riva Rocchi (blood pressure); HR, heart rate; SD, standard deviation; ABPM, ambulatory blood pressure monitoring
Table 2 Antihypertensive treatment and co-medication at baseline
Intention to treat Per protocol
Ramipril
(n = 1,350)
Diuretic
(n = 661)
Ramipril
(n = 1,029)
Diuretic
(n = 478)
Antihypertensive drugs
Ramipril (%) 76.2 0 100.0 0
CCB (%) 17.3 13.8 15.3 0
Diuretic (%) 0 72.3 0 100.0
Betablocker (%) 0.3 0 0 0
Central acting AH (%) 3.3 2.0 2.9 1.7
Alphablockers (%) 1.9 1.4 1.9 0.8
Co-Medication
Statins (%) 19.3 17.7 17.7 16.7
Anticoagulants (%) 3.2 5.4 2.8 5.0
Thienopyridines (%) 2.0 1.4 1.7 1.5
Aspirin (%) 21.7 20.4 20.5 18.4
Legend. CCB, calcium channel blocker; AH, antihypertensives
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HbA1c of 6.0 ± 0.7% in both groups at 4 years (Figure
3, lower panel). 34.9% of patients had an increase of >
10% of the HbA1c in the ramipril and 34.8% in the
diuretic based group at year 4. On the contrary 7.2% of
patients had a decrease of > 10% of the HbA1c in the
ramipril and 6.2% in the diuretic based group at year 4.
This mostly related to patients with a high HbA1c at
baseline.
Microalbuminuria
Albuminuria levels at baseline were higher in the rami-
pril group compared to the diuretic group (33.8 ± 131.4
vs.19.4 ± 38.2 mg/dl; p < 0.01). After 4 years follow up albuminuria was slightly reduced in the ramipril group
(23.6 ± 67.0 mg/dl; p < 0.05 vs. baseline; -30%), while it
was increased in the diuretic group (44.3 ± 255.4 mg/dl;
p < 0.01 vs. baseline; +128%).
Further secondary outcomes and adverse events
The difference in total mortality (2.0% with ramipril vs.
2.9% with diuretics) as well as differences in major car-
diovascular events (3.7% with ramipril vs. 5.0% with
diuretics) including first manifestation of symptomatic
coronary heart disease, peripheral arterial occlusive dis-
ease and cerebrovascular events was similar in both
treatment groups (p = n.s.), while showing a trend for
lower rates in the ramipril group. In a post hoc Kaplan-
Meier analysis grouping both mortality and cardiovascu-
lar events, the difference between the ramipril and the
diuretic treated group became significant in favour of
ramipril (p = 0.033) (Figure 4).
Serious adverse events (12.4 vs. 15.3%; p = 0.05) were
more frequent in the diuretic based treatment group (all
adverse events 25.6 vs. 26.6%; p = n.s.). The most
Figure 1 Prevalence of new-onset diabetes in patients during
the 4 year follow-up. Legend: White numbers within columns
indicate yearly incidence rates, patient numbers in italics; further
differences between diabetes prevalence rates for each year are
indicated together with the result of statistical testing.
Figure 2 Office blood pressure throughout the 4 year follow-
up. Legend: FU, follow-up; yr, year; RR, blood pressure (Riva Rocchi);
HR, heart rate; Diu, diuretic based therapy; Rami, ramipril based
therapy.
Figure 3 Changes in fasting blood glucose and HbA1c trough
years 1 to 4. Legend: FU, follow-up.
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class (Table 4) for serious adverse events were cardiac
disorders (24.4 vs. 25.7%; p = n.s.) followed by neo-
plasms (18.5 vs. 14.9%; p = n.s.), general disorders and
administration site conditions (19.6 vs. 25.7%; p = n.s.)
and nervous system disorders (14.9 vs. 28.7%; p < 0.05).
Discussion
Consistent with earlier studies [1,24,25] we found a sig-
nificant amount of patients developing overt diabetes
within the 4 year study period. We also confirmed a sig-
nificantly higher rate of new onset diabetes with a diure-
tic based antihypertensive treatment approach compared
to ramipril based therapy at the three year follow-up.
This finding was reflected by a continuous increase in
HbA1c over the 4 years study period. Although our
results are somewhat limited by the loss of significance
for differences at 4 years, we are essentially able to con-
firm for a real-world setting the results of previous ran-
domized, controlled trials, in which a reduction of new-
onset diabetes was reported for renin angiotensin block-
ing based treatment strategies in comparison to diuretics
and/or betablockers in pre-diabetic, hypertensive or car-
diovascular risk patients.
New onset diabetes in perspective
The results of ADaPT are in principal agreement with
prior randomized trials using ACE inhibitors or angioten-
sin receptor blockers (Table 5). These have been sum-
marized in several meta-analyses [8,24-29] of which the
one by Al-Mallah [24] is the most comprehensive and
the one by Tocci [25] the most recent which also
included the NAVIGATOR trial [17]. The results of both
meta-analyses were virtually identical although Al-Mallah
also included results of trials with active comparators
(diuretics, betablocker, calcium channel blockers) while
Tocci only considered placebo controlled trials. Al-Mal-
lah reported a relative risk of 0.78 (95%CI 0.70-0.88) for
the development of diabetes with ACE inhibitors and a
relative risk of 0.8 (95%CI 0.75-0.86) for angiotensin
receptor blockers versus non-RAS based treatments [24].
Table 4 Number of patients with adverse event (AE) or serious adverse event (SAE) during survey
Ramipril (n = 1,350) Diuretic (n = 661)
Type of adverse event n%n %
No AE 962 71.3 463 70.0
Any AE 388 28.7 198 30.0
Serious AE 168 12.4 101 15.3
Not serious 345 25.6 176 26.6
MedDRA
® primary System Organ Classes (SOC) V. 11.1 - (Serious) Adverse Events, n = 2011 (%) Ramipril Diuretic
AE SAE AE SAE
Musculosceletal and connective tissue disorders 6.52 0.74 11.95 0.61
Infections and infestations 6.22 0.37 9.98 0.45
Metabolism and nutrition disorders 5.78 0.22 8.02 1.06
Respiratory, thoracic and mediastinal disorders 5.93 0.22 3.03 0.45
Nervous system disorders 3.41 1.70 6.66 3.78
Gastrointestinal disorders 3.48 1.04 4.24 1.36
Cardiac disorders 3.04 2.74 4.54 3.18
Vascular disorders 3.26 1.48 2.57 1.36
General disorders and administration site conditions 2.07 1.93 3.48 3.03
Injury, poisoning and procedural complications 2.22 1.04 3.18 1.36
Surgical and medical procedures 2.00 0.89 2.87 1.51
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 1.93 2.22 2.12 2.12
Figure 4 Freedom from cardiovascular events. Legend: CV,
cardiovascular events and death.
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95%CI 0.7-1.0) and ARBs (OR 0.8; 95%CI 0.8-0.9)
reduced new-onset diabetes as compared to placebo [25].
These results are in agreement with the finding of an OR
of 0.83 seen in ADaPT.
There are two noteworthy findings in ADaPT that call
for an appreciation. First the incidence rate for diabetes
was about 3 times higher in the first year (17.3%) as com-
pared to subsequent years (5.1% second, 3.4% third and
7.2% in the fourth year). This is in contrast with results
of NAVIGATOR where incidence rates were about 9%
each year and was not different across years 1 to 5 [17].
Further incidence rates were also low in the first year of
DREAM and were progressively increasing through sub-
sequent years [1]. Therefore the increased incidence rate
in ADaPT during the first year is most likely artificial,
possibly triggered by a closer surveillance of patients
entering the observation. Another explanation might be
the employed pre-selection of high risk patients by the
PreDisc-Score in ADaPT. This might have distorted the
natural time course of diabetes onset. Actually the overall
diabetes incidence rate over 4 years was quite similar in
ADaPT and NAVIGATOR/DREAM [1,17]. Second,
while 3 year results were promising with respect to differ-
ences in incidence rates between ramipril and the diure-
tic group (24.4 vs. 29.5%, Δ 4.7%; p < 0.05), 4 year results
were nominally but not statistically different (31.9 vs.
35.4%, Δ 3.5%; p = n.s.). This can be interpreted in two
different directions: 1) The difference found at a median
treatment duration of 3 years is “by chance” and the non-
significant difference at months 12, 24 and 48 reflects the
true effect of ramipril vs. diuretic based treatment on the
incidence of diabetes. This is somewhat in line with the
finding of a non-significant difference in fasting blood
glucose levels in either group and the virtually identical
trend for HbA1c which increased in parallel over time (p
< 0.001). 2) On the contrary the 3 year result may also
reflect the true effect of ramipril vs. diuretic based treat-
ment. This is notion is supported by the nominally but
statistically not different rate at year 4 (Δ 3.5%), which
might be due the loss of 57.7% patients between year 3
and 4 which will limit the statistical power of this com-
parison. Further this interpretation is in line with the
aforementioned meta-analyses [24,25] and 2 out of 3
trials reporting the effects of ramipril [1,30-32]. However,
overall our study is small compared to other trials having
reported outcomes with new-onset diabetes as an end-
point questioning that statistical power at year 4 is suffi-
cient to actually capture differences between treatments.
The possibility for physicians in this real world trial to
add a calcium channel blockers to the ramipril group and
a betablocker to the diuretic group may be perceived to
Table 5 Results in perspective (adapted from [24])
RAS blocking agent Control Number of patients Follow-up RR (95%CI)
SOLVD [36] Enalapril Placebo 4,228 3.4 0.26 (0.13-0.53)
AASK [30] Ramipril Betablocker/
Amlodipine
1,094 4.1 0.64 (0.45-0.90)
HOPE [31] Ramipril Placebo 9,297 5 0.67 (0.52-0.85)
ANBP2 [37,38] Enalapril Diuretic 6,083 4.1 0.70 (0.56-0.86)
ALLHAT [39] Lisinopril Chlorthalidone/Amlodipine 33,357 4.9 0.75 (0.59-0.94)
IMAGINE [40] Quinapril Placebo 2,553 2.95 0.79 (0.48-1.29)
ADaPT [22] Ramipril Betablockers/
Diuretic
2,011 3 0.83 (0.65-0.80)
PEACE [41] Trandolapril Placebo 8,290 4.8 0.85 (0.74-0.97)
CAPPP [42] Captopril Betablockers/
Diuretic
10,985 6.1 0.89 (0.78-1.03)
DREAM [1,32] Ramipril Placebo 5,269 3 0.93 (0.82-1.04)
STOP-2 [43] Enalapril/
Lisinopril
Betablockers/
Diuretic
6,614 5 0.95 (0.72-1.26)
ALPINE [44] Candesartan HCTZ 392 1 0.13 (0.02-0.99)
CASE-J [45] Candesartan Amlodipine 4,703 3.2 0.65 (0.44-0.98)
LIFE [46] Losartan Atenolol 9,193 4.8 0.75 (0.64-0.88)
CHARM [47] Candesartan Placebo 7,599 3.2 0.81 (0.66-0.99)
SCOPE [48] Candesartan Placebo 4,937 3.7 0.81 (0.62-1.06)
VALUE [16] Valsartan Amlodipine 15,245 4.2 0.81 (0.74-0.89)
PRoFESS [49] Telmisartan Placebo 20,332 2.5 0.83 (0.65-1.04)
TRANSCEND [50] Telmisartan Placebo 5,926 4.6 0.86 (0.72-1.02)
NAVIGATOR [17] Valsartan Placeno 9,306 5 0.86 (0.80-0.92)
Legend. RR, relative risk; HCTZ, hydrochlorothiazide
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Page 7 of 11confound the principal comparison of this investigation
and limit its interpretation. This is because betablockers
have been demonstrated to adversely affect glucose con-
trol and calcium channel blockers, which were neutral
with respect to the development of diabetes in a large
network meta-analysis published by Elliott [8] and sup-
plemented by Lam [9], have been reported to have a
potentially beneficial effect on glucose tolerance and
insulin sensitivity. Evidence was provided by a recent
study in 17 non-diabetic patients with essential hyperten-
sion, where the third-generation calcium channel blocker
azelnidipine proved to be more beneficial than second
generation amlodipine [33]. While these results are of
potential relevance for the interpretation of our findings,
they may not fully apply: Only 15.3% of those receiving
ramipril had a calcium channel blocker (mostly the sec-
ond generation felodipine) added to their treatment.
Moreover no patient in the diuretic group actually
received an additional betablocker. On the other hand
our findings may enforce the notion that a combination
of an ACE inhibitor with a calcium channel blocker is
actually beneficial with respect to the development of
diabetes and diabetic complications as has been recently
suggested by a trial comparing the combination of the
third generation manidipine and delapril with delapril
monotherapy or placebo [34]. In this trial, including
exclusively hypertensive type-2 diabetic patients, combi-
nation treatment was able to ameliorate diabetic compli-
cations better than placebo (major cardiovascular events
HR 0.17; 95%CI 0.04-0.78).
Based on these considerations we are convinced that the
effects of ramipril over a diuretic based antihypertensive
treatment can also be observed in clinical practice. As
pointed out by Al-Mallah the number of patients to pre-
vent one case of new onset diabetes (50-100) is too small
to justify their use for simple prevention [24]. However,
the use of these medications to treat hypertensive and
CHF patients at risk for diabetes can be recommended.
Because angiotensin receptor recently went off-patent
there is no future need to justify their use based on cost-
effectiveness considerations.
Cardiovascular events and death
Any cardiovascular events were reduced with ramipril vs.
diuretic based treatment in our study (p = 0.033). How-
ever, these results have to be considered with caution
since they were determined from cases announced to the
trialists as adverse or serious adverse events and serious
underreporting of adverse events has been documented
for observational studies [35]. Further a number of
patients were lost to follow-up, introducing considerable
uncertainty into these results. Further most of the other
trials reporting incidence rates for diabetes failed to show
a cardiovascular benefit. On the other hand the finding is
in line with the most recent meta-analysis which included
11 trials and 84,363 patients which compared active
treatment versus placebo [25]. Tocci et al found that
active treatment using ACE inhibitors or angiotensin
receptor blockers significantly reduced cardiovascular
mortality (OR 0.9; 95%CI 0.8-1.0; p < 0.01) and had a
favorable impact on non-CV mortality (OR 0.7; 95%CI
0.9-1.0; p = 0.2) as compared to placebo [25]. The find-
ings are further also in line with the results of HOPE
comparing ramipril to placebo where treatment with
ramipril reduced the rates of death from cardiovascular
causes (relative risk 0.74; p < 0.001), myocardial infarc-
tion (RR 0.80; p < 0.001), stroke (RR 0.68; p < 0.001),
death from any cause (RR 0.84; p = 0.005), and complica-
tions related to diabetes (6.4 vs. 7.6%; RR 0.84; p = 0.03)
[31]. Interestingly there was also a reduced event rate in
cardiovascular high risk patients (OR 0.8; 95%CI 0.7-0.9)
observed in the meta-analysis by Tocci et al. [25].
Pre-selection of high risk patients
Given that 50 to 100 patients have to be treated with RAS
blocking agents to prevent one case of new onset diabetes
[24] might call for a pre-selection of patients. For this pur-
pose the oral glucose tolerance test (OGTT) is useful but
it is not convenient under daily practice conditions and
the determination of fasting glucose or the HbA1c alone
yields low sensitivity (62 and 58% respectively) [21].
Therefore patients were selected for ADaPT based on
the PreDisc-Score, that closely correlates to the outcome
of an OGTT [21]. The PreDisc-Score has a sensitivity, spe-
cificity and positive and/or negative predictive value in the
range of 80% [21]. However, compared to the original Pre-
DiSc score, we had to adapt the score based on practical
experiences in the initiation phase of the study: first,
HbA1c was to be measured in a central laboratory instead
of the originally planned local determination due to wide
variation in locally determined values. Second, the age cri-
terion was reduced to 45 years or older in order to acceler-
ate the inclusion rate.
The utility of the PreDisc-Score in the present has to
be considered on the background of a number of vari-
ables. 1) Non-interventional studies such as ADaPT are
prone to unknown bias because they are non-randomized
and non-blinded. A possible result is a blurred estimate
of the true effect which might underestimate differences
between treatment groups. To cope with this the Pre-
Disc-Score appears appropriate to select a patient popu-
lation at high risk. 2) Despite the selection of high risk
patients incidence rates within 4 years are not different
from trials such as NAVIGATOR/DREAM [1,17], which
might question this concept. Actually the adaption of the
score to allow patients between 45 and 55 to enter the
observation was never prospectively tested and has to be
regarded as a limitation.
Zidek et al. Cardiovascular Diabetology 2012, 11:1
http://www.cardiab.com/content/11/1/1
Page 8 of 11Limitations
Limitations of our study are mainly the observational,
not randomized character, which doesn’tp r e v e n tb i a s
through unknown impacting parameter. Yet the study
goal was to confirm in a large cohort reflecting daily
medical practice the findings of large existing rando-
mized clinical trials. The only noteworthy differences in
the baseline characteristics of both treatment groups
seem to be a slightly higher proportion of male patients
(51.4 vs. 42.6%) and higher percentage of calcium chan-
nel blocker use in the ramipril group (18.6 vs. 15.3%).
We do not know if this affected the outcome in any
relevant perspective, but such minor differences can
never completely be ruled out in observational registries.
As mentioned before a noteworthy limitation for inter-
pretation of the presented outcome data is the fact, that
the cardiovascular event and mortality analysis was only
based on the AE/SAE reporting.
Conclusions
T h ep r e s e n ts t u d yd o c u m e n t sah i g hi n c i d e n c er a t ef o r
type-2 diabetes during the course of a four year observa-
tional period. Our key finding is in line with the large
prospective randomized studies such as ASCOT-BPLA,
VALUE, DREAM and NAVIGATOR and meta-analyses,
which reported a significantly reduced incidence of new-
onset diabetes with RAS based pharmacotherapy com-
pared to diuretics, beta-blockers or placebo in pre-dia-
betic, hypertensive or cardiovascular risk patients.
Patients at risk for the development of diabetes, who are
identified with the PreDisc-Score should preferably be
treated first line with ramipril rather than a diuretic or
beta blocking agent for arterial hypertension.
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